New immune therapy takes on advanced liver cancer
NCT ID NCT05033522
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study tests an experimental immunotherapy called AlloStim against standard treatments (sorafenib, lenvatinib, or chemotherapy) in 150 Asian adults with advanced liver cancer that cannot be treated with surgery or local therapies. Participants are randomly assigned to receive either AlloStim or a standard drug. The main goal is to see if AlloStim helps people live longer and improves their quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chiangmai University
Chiang Mai, Thailand
-
Columbia Asia Bukit Rimau
Shah Alam, Selangor, 40460, Malaysia
-
Naresuan University Hospital
Phitsanulok, Tha Pho, 65000, Thailand
-
Prince of Songkla University (Songklanagarind Hospital)
Hat Yai, Changwat Songkhla, 90110, Thailand
-
Siriraj Hospital
Bangkok Noi, Bangkok, 10700, Thailand
-
Songklanagarind Hospital
Khon Kaen, Thailand
-
Sultan Ismail Hospital
Johor Bahru, Johor, 81100, Malaysia
-
Sultanah Bahiyah Hospital
Alor Star, Kedah, 05460, Malaysia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AlloStim immunotherapy (a type of immune cell therapy)
What this could lead to
If it works, this could offer a new treatment option for advanced liver cancer that may improve survival and quality of life.
What could go wrong
The trial is currently suspended, and it is still in early-to-mid stages. The immunotherapy may not work better than existing drugs, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.